Dyadic International Inc DYAI

Healthcare Biotechnology

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

NDAQ:DYAI - Post by User

Dyadic International Inc

<< Previous

Bullboard Posts

Next >>

Post by CapitalHunter29on Nov 25, 2024 10:53am

21 Views

Post# 36329054

Bullish Opportunities in $DYAI and $MYNZ

$DYAI is gaining traction after securing a $3M grant, breaking resistance at $1.58-1.60 with rising volume—next stop $1.90-2.00 if momentum holds. $MYNZ is leveraging its partnership with TMO, showing strong support at 0.20 while RSI signals bullish divergence.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record